Page last updated: 2024-08-25

grepafloxacin and Chronic Disease

grepafloxacin has been researched along with Chronic Disease in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's2 (33.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H1
Amantea, MA; Chodosh, S; Collins, DA; Forrest, A; Schentag, JJ1
Breisch, S; Cranfield, R; Langan, CE; Pettit, R1
Bagby, B; Bettis, R; Collins, JJ; DeAbate, CA; Fleming, H; Giguere, G; Munk, ZM; Munn, NJ; Riffer, E1
Ballow, CH; Forrest, A; Hyatt, JM; Peloquin, CA; Sands, MF; Schentag, JJ; Tran, JQ1
Chodosh, S; Forrest, A; Hyatt, JM; Meinl, B; Schentag, JJ1

Trials

5 trial(s) available for grepafloxacin and Chronic Disease

ArticleYear
Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
    Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:1

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bronchitis; Bronchodilator Agents; Chronic Disease; Ciprofloxacin; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Theophylline; Treatment Outcome

1998
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Infective Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Male; Middle Aged; Models, Biological; Piperazines; Quinolones; Time Factors

1997
Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 40 Suppl A

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Bacteria; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Hematologic Tests; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillins; Piperazines; Quinolones; Treatment Outcome

1997
Effectiveness of short-course therapy (5 days) with grepafloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis.
    Clinical therapeutics, 1999, Volume: 21, Issue:1

    Topics: Acute Disease; Adult; Aged; Anti-Infective Agents; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Middle Aged; Piperazines; Quinolones

1999
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
    The Journal of antimicrobial chemotherapy, 2000, Volume: 45

    Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Bronchitis; Chronic Disease; Clarithromycin; Female; Fluoroquinolones; Haemophilus; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Piperazines; Serum Bactericidal Test; Sputum

2000

Other Studies

1 other study(ies) available for grepafloxacin and Chronic Disease

ArticleYear
Pharmacokinetic/pharmacodynamic predictors of time to clinical resolution in patients with acute bacterial exacerbations of chronic bronchitis treated with a fluoroquinolone.
    International journal of antimicrobial agents, 2000, Volume: 16, Issue:3

    Topics: Anti-Infective Agents; Bronchitis; Chronic Disease; Controlled Clinical Trials as Topic; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Piperazines; Predictive Value of Tests; Treatment Outcome

2000